Biotech Values

[jbog]

Revance expects cash burn for 2018 to be in the range of $117 to $137 million while at this time the cash burn for 2017 was in the range of $102 to $112 million. I'm surprised they didn't tighten up the 2018 range considering they are in their 4th quarter. The total operating charge is over the $100 mil at the end of Q3 so they'll come in at the upper section of the range.

With this as a basis, and the possibility of building a sales team I would expect 2019 to be somewhat if not greatly higher. The key is if they partner or not.